|
|
Clinical observation of dexmedetomidine in prevention of nausea and vomiting after laparoscopic hysteromyomectomy |
JIANG Ye1,2,WANG Qingxiu1, and HE Hong2 |
1.Tongji University Medical School, Shanghai 200092,China; 2. Department of Gynecology, Changning Maternal and Child Health Hospital, Shanghai 051000, China |
|
|
Abstract Objective To study the effect of subclinical doses of dexmedetomidine on the prevention of nausea and vomiting after laparoscopic myomectomy.Methods One hundred and twenty patients scheduled to undergo laparoscopic myomectomy between June 2016 and December 2017 were selected. These patients were randomly divided into three groups: the dexmedetomidine group, the ramosetron group , and the metoclopramide group. In the dexmedetomidine group, the background dose was 0.4 μg/kg, and infusion was completed slowly (3-5 min). The ramosetron group was given remerstom 0.3 mg 30 min before the end of the operation. The metoclopramide group was given metoclopramide 20 mg 30 min before the end of surgery. The incidence of nausea and vomiting was observed in these three groups of patients 0-1 h, >1-3 h, >3-6 h, >6-12 h after extubation.Results There was no statistically significant difference in the incidence of postoperative nausea and vomiting between the three groups 3 h after surgery, but the incidence of postoperative nausea and vomiting in the dexmedetomidine group and the ramosetron group was significantly lower than that in the metoclopramide group (P<0.05).Conclusions Intravenous injection of some dose of dexmedetomidine before induction and intraoperative maintenance of small-dose infusion or a dose of ramosetron or metoclopramide (wintin 3 hour) 30 min before the end of surgery can all effectively prevent nausea and vomiting induced by laparoscopic hysteromyoma resection three hours after surgery. Dexmedetomidine and ramosetron are more effective than metoclopramide.
|
Received: 20 January 2018
|
|
|
|
|
[1] |
Gan T J. Risk factors for postoperative nausea and vomiting [J]. Anesth Analg, 2006, 102(6):1884-1898.
|
[2] |
傅树英,葛圣金. 术后恶心呕吐的机制与防治研究进展[J]. 上海医学, 2016,39(4):243-247.
|
[3] |
郝 静,吴 浩,马正良, 等. 右美托咪定对后腹腔镜手术患者术中血流动力学的影响[J]. 中国微创外科杂志,2011,11(3): 215-219.
|
[4] |
吴新民,罗爱伦,田玉科,等. 术后恶心呕吐防治专家意见[J]. 临床麻醉学杂志,2012, 28(4): 413-416.
|
[5] |
De Winter B Y,Van Den Wijngaard R M, De Jonge W J. Intestinal mast cells in gut inflammation and motility disturbances[J] . Biochim Biophys Acta, 2012, 1822(1): 66-73.
|
[6] |
Massad I M,Mobsem W A,Basba A S. A balanced anesthesia with dexmedetimidine decreases postoperative nausea and vomiting after laparoscopic surgery.2009,30(12):1537-1541
|
[7] |
曹 磊,范平雅,谭光宏, 等. 小剂量右美托咪定对宫颈癌微创手术患者恶心呕吐影响的研究[J]. 重庆医学, 2017, 46(36): 5068-5070.
|
[8] |
Sanger G J, Andrew P L. Treatment of nausea and vomiting: gaps in our knowledge [J]. Auton Neurosci, 2006, 129(1-2): 3-16.
|
[9] |
陈明慧,俞红丽,常 涛,等. 右美托咪定用于预防腹腔镜胆囊切除术后恶心呕吐的效果[J]. 临床麻醉学杂志, 2017, 33(3):261-263.
|
[10] |
Bhandari P, Bingham S, Andrew P L. The neuropharmacology of loperamide-induced emesis in the ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors[J]. Neuropharcology,1992,31(8):735-742.
|
[11] |
田 平,刘 晔,李明颖,等. 手术后患者恶心呕吐相关因素分析[J]. 山东医药,2009, 49(26):97-98.
|
[12] |
梁晨曦,刘丽丹,穆 莹,等. 预防性给予止吐药物的妇科患者发生术后恶心呕吐的危险因素[J].中国医科大学学报,2017,11(46):1032-1044.
|
|
|
|